Targeting dopamine receptor D2 as a novel therapeutic strategy in endometrial cancer
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Targeting dopamine receptor D2 as a novel therapeutic strategy in endometrial cancer
Authors
Keywords
-
Journal
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
Volume 40, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-02-09
DOI
10.1186/s13046-021-01842-9
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Targeting dopamine receptor D2 as a novel therapeutic strategy in endometrial cancer
- (2021) Stuart R. Pierce et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Endoplasmic Reticulum Stress Signaling in Cancer Cells
- (2020) Scott A. Oakes AMERICAN JOURNAL OF PATHOLOGY
- Dual metabolic reprogramming by ONC201/TIC10 and 2-Deoxyglucose induces energy depletion and synergistic anti-cancer activity in glioblastoma
- (2020) Maximilian Pruss et al. BRITISH JOURNAL OF CANCER
- Cancer statistics, 2020
- (2020) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Progress in Genetic Polymorphisms Related to Lipid Disturbances Induced by Atypical Antipsychotic Drugs
- (2020) Nana Li et al. Frontiers in Pharmacology
- FDA Approval Summary: Pembrolizumab plus Lenvatinib for Endometrial Carcinoma, a Collaborative International Review under Project Orbis
- (2020) Shaily Arora et al. CLINICAL CANCER RESEARCH
- Activation of dopamine receptor 2 (DRD2) prompts transcriptomic and metabolic plasticity in glioblastoma
- (2019) Seamus P. Caragher et al. JOURNAL OF NEUROSCIENCE
- Mitochondrial Protease ClpP is a Target for the Anticancer Compounds ONC201 and Related Analogues
- (2019) Paul R. Graves et al. ACS Chemical Biology
- Mitochondrial ClpP-Mediated Proteolysis Induces Selective Cancer Cell Lethality
- (2019) Jo Ishizawa et al. CANCER CELL
- The Direct Molecular Target for Imipridone ONC201 Is Finally Established
- (2019) Shaomeng Wang et al. CANCER CELL
- First clinical experience with DRD2/3 antagonist ONC201 in H3 K27M–mutant pediatric diffuse intrinsic pontine glioma: a case report
- (2019) Matthew D. Hall et al. Journal of Neurosurgery-Pediatrics
- Annual Report to the Nation on the Status of Cancer, 1999–2015, Featuring Cancer in Men and Women ages 20–49
- (2019) Elizabeth Ward et al. JNCI-Journal of the National Cancer Institute
- Safety and enhanced immunostimulatory activity of the DRD2 antagonist ONC201 in advanced solid tumor patients with weekly oral administration
- (2019) Mark N. Stein et al. Journal for ImmunoTherapy of Cancer
- Pediatric and adult H3 K27M-mutant diffuse midline glioma treated with the selective DRD2 antagonist ONC201
- (2019) Andrew S. Chi et al. JOURNAL OF NEURO-ONCOLOGY
- Biological activity of weekly ONC201 in adult recurrent glioblastoma patients
- (2019) Isabel Arrillaga-Romany et al. NEURO-ONCOLOGY
- Integrated stress response and immune cell infiltration in an ibrutinib-refractory mantle cell lymphoma patient following ONC201 treatment
- (2018) Jorge E. Romaguera et al. BRITISH JOURNAL OF HAEMATOLOGY
- Osteocyte-Driven Downregulation of Snail Restrains Effects of Drd2 Inhibitors on Mammary Tumor Cells
- (2018) Shengzhi Liu et al. CANCER RESEARCH
- A phase II study of frontline paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus, or ixabepilone/carboplatin/bevacizumab in advanced/recurrent endometrial cancer
- (2018) Carol Aghajanian et al. GYNECOLOGIC ONCOLOGY
- Dose intensification of TRAIL-inducing ONC201 inhibits metastasis and promotes intratumoral NK cell recruitment
- (2018) Jessica Wagner et al. JOURNAL OF CLINICAL INVESTIGATION
- ONC201 Targets AR and AR-V7 Signaling, Reduces PSA, and Synergizes with Everolimus in Prostate Cancer
- (2018) Avital Lev et al. MOLECULAR CANCER RESEARCH
- Role of Dopamine Receptors in the Anticancer Activity of ONC201
- (2018) Christina Leah B. Kline et al. NEOPLASIA
- Dopamine receptor D2 genetic variations is associated with the risk and clinicopathological variables of urothelial cell carcinoma in a Taiwanese population
- (2018) Min-Che Tung et al. International Journal of Medical Sciences
- Thioridazine inhibits self-renewal in breast cancer cells via DRD2-dependent STAT3 inhibition, but induces a G1 arrest independent of DRD2
- (2018) Matthew Tegowski et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Dopamine Receptor D5 is a Modulator of Tumor Response to Dopamine Receptor D2 Antagonism
- (2018) Varun Vijay Prabhu et al. CLINICAL CANCER RESEARCH
- Investigational PI3K/AKT/mTOR inhibitors in development for endometrial cancer
- (2018) Fabio Barra et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- The behaviour of Tenax as food simulant in the migration of polymer additives from food contact materials by means of gas chromatography/mass spectrometry and PARAFAC
- (2018) L. Rubio et al. JOURNAL OF CHROMATOGRAPHY A
- Dopamine receptor type 2 (DRD2) and somatostatin receptor type 2 (SSTR2) agonists are effective in inhibiting proliferation of progenitor/stem-like cells isolated from nonfunctioning pituitary tumors
- (2017) E. Peverelli et al. INTERNATIONAL JOURNAL OF CANCER
- Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1–Positive Endometrial Cancer: Results From the KEYNOTE-028 Study
- (2017) Patrick A. Ott et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase 2 study of the first imipridone ONC201, a selective DRD2 antagonist for oncology, administered every three weeks in recurrent glioblastoma
- (2017) Isabel Arrillaga-Romany et al. Oncotarget
- Dopamine receptor type 2 (DRD2) inhibits migration and invasion of human tumorous pituitary cells through ROCK-mediated cofilin inactivation
- (2016) E. Peverelli et al. CANCER LETTERS
- Expression of DRD2 Is Increased in Human Pancreatic Ductal Adenocarcinoma and Inhibitors Slow Tumor Growth in Mice
- (2016) Pouria Jandaghi et al. GASTROENTEROLOGY
- ATF4 induction through an atypical integrated stress response to ONC201 triggers p53-independent apoptosis in hematological malignancies
- (2016) Jo Ishizawa et al. Science Signaling
- Everolimus exhibits anti-tumorigenic activity in obesity-induced ovarian cancer
- (2016) Hui Guo et al. Oncotarget
- Discovery and clinical introduction of first-in-class imipridone ONC201
- (2016) Joshua E. Allen et al. Oncotarget
- ATF4 induction through an atypical integrated stress response to ONC201 triggers p53-independent apoptosis in hematological malignancies
- (2016) Jo Ishizawa et al. Science Signaling
- Genome-wide shRNA screen revealed integrated mitogenic signaling between dopamine receptor D2 (DRD2) and epidermal growth factor receptor (EGFR) in glioblastoma
- (2015) Jie Li et al. Oncotarget
- Activation of PI3K/Akt/mTOR Pathway and Dual Inhibitors of PI3K and mTOR in Endometrial Cancer
- (2014) Jiezhong Chen et al. CURRENT MEDICINAL CHEMISTRY
- Metabolic Reprogramming of Macrophages
- (2014) Alex J. Freemerman et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Classification of endometrial carcinoma: more than two types
- (2014) Rajmohan Murali et al. LANCET ONCOLOGY
- Dopamine D2 Receptor-mediated Epidermal Growth Factor Receptor Transactivation through a Disintegrin and Metalloprotease Regulates Dopaminergic Neuron Development via Extracellular Signal-related Kinase Activation
- (2013) Sehyoun Yoon et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Integrated genomic characterization of endometrial carcinoma
- (2013) Gad Getz et al. NATURE
- Dual Inactivation of Akt and ERK by TIC10 Signals Foxo3a Nuclear Translocation, TRAIL Gene Induction, and Potent Antitumor Effects
- (2013) J. E. Allen et al. Science Translational Medicine
- Incidence of Cancer in Patients With Schizophrenia and Their First-Degree Relatives: A Population-Based Study in Sweden
- (2012) Jianguang Ji et al. SCHIZOPHRENIA BULLETIN
- The incidence and relative risk factors for developing cancer among patients with schizophrenia: A nine-year follow-up study
- (2011) Frank Huang-Chih Chou et al. SCHIZOPHRENIA RESEARCH
- Endometrial Carcinoma: A Review of Chemotherapy, Drug Resistance, and the Search for New Agents
- (2010) K. M. Moxley et al. ONCOLOGIST
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now